Key Highlights

  • Shares climbed 11.04% to USD 7.67 in pre-market trading on November 3, 2026.
  • The company agreed on November 3, 2026 to acquire most of Vantive's hemodialysis Business outside dialyzers.
  • The deal is expected to close in mid-2027, subject to regulatory approvals.
  • Second quarter 2026 net sales were USD 17.8 million, up 11%.
  • Cash, equivalents and investments totaled USD 24.8 million on June 30, 2026.

What Moved the Shares in Pre-Market Trading (up USD 0.7626, 11.04%)

Rockwell Medical (NASDAQ:RMTI) rose 11.04% to USD 7.67 in pre-market trading on November 3, 2026, compared with the November 2, 2026 close. The company announced the same day that it had signed a definitive agreement with Vantive.

The price and financing terms were not disclosed in the release content reviewed, so the market is reacting to the strategic scale of the transaction rather than to stated economics.

The Vantive Agreement in Detail

According to a press release dated November 3, 2026, Rockwell will acquire Vantive's hemodialysis concentrates, hemodialysis monitors and water treatment systems, along with related consumables and technical services. The Medolla, Italy Manufacturing Facility transfers to Rockwell on completion.

Vantive's dialyzer portfolio, including the Theranova dialyzer, is excluded from the sale. The parties expect the transaction to close in mid-2027, subject to required regulatory approvals and other customary conditions.

Rockwell CEO Mark Strobeck described the company as singularly focused on hemodialysis, while Vantive CEO Chris Toth said the announcement sharpens Vantive's ambitions.

Business Background and Recent Results

Rockwell, based in Wixom, Michigan, develops, manufactures and distributes hemodialysis products, mainly concentrates, to dialysis providers worldwide. It exhibited at ASN Kidney Week in Denver from October 21 to 25, 2026, according to a company release dated October 14, 2026.

For the quarter ended June 30, 2026, net sales were USD 17.8 million, up 11% from USD 16.1 million, and gross Margin rose to 18% from 16%. The net loss narrowed to USD 1.2 million, and Operating Cash Flow was positive at USD 2.1 million.

The company reiterated 2026 guidance of USD 70 million to USD 75 million in net sales, gross margin of 18% to 22%, and adjusted EBITDA of USD 1 million to USD 2 million. It will report third quarter results on November 12, 2026.

Balance Sheet and Risk Considerations

Cash, equivalents and investments were USD 24.8 million at June 30, 2026. Because the purchase price has not been identified, how the company will fund an Acquisition of this scale is an open question, and any Equity issuance could dilute current holders.

The shares carry a post-split profile: a 1-for-10 Reverse Stock Split took effect on July 1, 2026, and the company regained Nasdaq minimum bid compliance on July 20, 2026. Integration across a new Italian plant and several product lines adds execution risk.

What to Watch Next

Key items include disclosure of the purchase price, financing details and any regulatory filings tied to the transaction. Further detail may come on the call for third quarter results on November 12, 2026.

Investors will also watch whether the pre-market gain lasts in regular trading and how the 2026 guidance evolves.